Shots:
Evotec has invested $20.96M in Sernova & will contribute to cell manufacturing along with clinical development funding. Both companies will share profits equally & Evotec participates in the clinical research program
Sernova to acquire an exclusive option to license Evotec’s iPSC-based beta cells for use with its Cell Pouch system to treat diabetes. The pre-clinical development program will be jointly funded until IND acceptance
The collaboration will combine Evotec’s iPSC-based beta cells with Sernova’s cell pouch device to develop off-the-shelf iPSC-based beta cell replacement therapy for insulin-dependent diabetes. Sernova is currently conducting a P-I/II study at the University of Chicago
Ref: Accesswire | Image: Evotec
